Ross Baker, PhD, MBA

Investigating Patient Characteristics as Predictors of Engagement Response to Adjunctive Brexpiprazole in Major Depressive Disorder

Background: Treatment with adjunctive brexpiprazole in major depressive disorder (MDD) has been shown to improve 'patient engagement', a concept related to one‚Äôs energy, interest, and o...

Ross Baker , PhD, MBA;

Jessica Reed , PhD;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Dalei Chen , PhD;

10/08/2020

Effects of Aripiprazole Once-monthly (AOM) Across Manic Symptoms in Patients with Bipolar I Disorder (BP-I)

Background: The established role of oral aripiprazole in the treatment of Bipolar I disorder (BP-I) and the potential for a long-acting injectable formulation to improve adherence and pre...

Ross Baker , PhD, MBA;

Maninder Malik , PhD;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

03/01/2019

Good, moderate, and poor functioning of adult patients with schizophrenia treated with aripiprazole once-monthly or paliperidone palmitate once-monthly in the Qualify study

Introduction QUALIFY was a 28-week, randomized, open-label, rater-blinded, head-to-head study (NCT01795547) evaluating effectiveness of aripiprazole once-monthly (AOM 400) vs paliperidone...

Simon Nitschky Schmidt , PhD;

Lizbeth Arias , MD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Jessica Madera , MD;

10/08/2020

Characteristics of Patients in Recovery Versus Patients With Recurrence in a Randomized Placebo-Controlled Study With Aripiprazole Once-Monthly as Maintenance Treatment for Bipolar I Disorder

Aims. To describe the background and clinical characteristics of patients who did versus those who did not have a recurrence of a mood episode during up to 52 weeks of maintenance treatme...

Peter Zhang , PhD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Jessica Madera , MD;

Mauricio Tohen , MD, DrPH, MBA;

03/01/2019

Functioning in de novo and rollover patients with bipolar I disorder receiving aripiprazole once-monthly in a 52-week, open-label study

Objectives: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable formulation of aripiprazole licensed in the US, Canada and Australia for maintenance treatment of adults...

Maxine Chen , PhD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

10/08/2020

Assessment of Functional Recovery After Long-term Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder

Background: Functional assessment is complex and often overlooked in patients with bipolar I disorder. The Functioning Assessment Short Test (FAST) assesses optimal functioning in these p...

Peter Zhang , PhD;

Ross Baker , PhD, MBA;

Thomas Brown , PhD;

Mauricio Tohen , MD, DrPH, MBA;

Pedro Such , MD;

Jessica Madera , MD;

Craig Surman , MD;

03/01/2019

Examining Depressive Symptoms Across Diagnostic and Statistical Manual Indications: Treatment Effects of Brexpiprazole in Patients With Major Depressive Disorder and Schizophrenia

Background: The NIMH Research Domain Criteria (RDoC) framework could be used to recategorize symptoms across the established DSM criteria for neuropsychiatric disorder indications. This p...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Malaak Brubaker , PhD;

Dalei Chen , PhD;

Ross Baker , PhD, MBA;

Ruth Duffy , PhD;

10/08/2020

Efficacy of Adjunctive Brexpiprazole in Adults With MDD: Improvement of Patient Engagement Based on Selected Items From the Inventory of Depressive Symptomatology Self-Report (IDS-SR) Scale

Objective: These post-hoc analyses used relevant items from the IDS-SR to explore whether treatment with adjunctive brexpiprazole in patients with MDD has potential to improve a new conce...

Anne Pedersen , MSc;

Klaus Groes Larsen , PhD;

Anna-Greta Nylander , PhD;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Dalei Chen , PhD;

Ross Baker , PhD, MBA;

Roger McIntyre , MD, FRCPC;

11/22/2019

Analysis of Sexual Function in a Study With Aripiprazole Once-Monthly Versus Paliperidone Palmitate Once-Monthly

Introduction: Sexual dysfunction is a common side effect of antipsychotic treatment and may contribute to non-adherence. In the QUALIFY study (NCT01795547) the effectiveness of aripiprazo...

Pedro Such , MD;

Jessica Madera , MD;

Ross Baker , PhD, MBA;

Heather Fitzgerald ;

Louise Rosenberg Christ , PhD;

11/22/2019

Short- and Long-Term Metabolic Changes in Patients with MDD Treated with Adjunctive Brexpiprazole or Adjunctive Aripiprazole: An Indirect Comparison

Objective: We aimed to describe metabolic changes observed during short- and long-term studies of brexpiprazole and aripiprazole in patients with MDD.

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Peter Zhang , PhD;

Erin MacKenzie , PhD;

Francois Therrien , PharmD;

Ross Baker , PhD, MBA;

11/22/2019